Nurse Practitioner Project
Resume:
CURRICULUM VITAE
TRACY MARIE JONES, MSN, ARNP
Riverview, FL 33578
ac6q7m@r.postjobfree.com
Cell 813-***-****
EDUCATION
Master of Science in Nursing, University of Tampa, Tampa FL; graduation August
2013--#1 in class with 4.0 GPA
Associate of Science in Nursing, Southwest Illinois College, Belleville, IL; graduation
May 2005--#1 in class with 4.0 GPA
Bachelor of Science in Business Administration, Chapman College, Orange, CA;
graduated May 1990--magna cum laude graduate
EXPERIENCE
Nov 13-Jun 18 Advanced Registered Nurse Practitioner, Department of Neurology; Ataxia Research Center and Movement Disorders Clinic, University of South Florida, Tampa, FL 33612 - Managed the care of neurological patients with movement disorders such as Parkinson's disease, essential tremor, ataxias, dystonia, peripheral neuropathy.
Jan 08-Nov 13 Staff Nurse, Neuro/Trauma ICU, Tampa General Hospital, Tampa, FL 33606--Provided quality, professional critical care to patients of the highest acuity.
Nov 06-Jan 08 Clinical Nurse Family Practice/Urgent Care, Cannon AFB, NM 88101-Care and education of patients across the lifespan to include diabetes, asthma, Coumadin and assessment and evaluation of patients with urgent medical needs.
Aug 05-0ct 06 Staff Nurse in the Surgical Unit, Plains Regional Hospital, Clovis, NM 88101-Care of pre/postoperative patients in hospital setting
LICENSES/CERTIFICATIONS
--Advanced Registered Nurse Practitioner- Family, certified-FL: ARNP 9263957
--American Association of Nurse Practitioners Certification, Family Nurse Practitioner-
#Fl013169
--Basic Life Support (BLS)- provider, expires 5/2019
--Advanced Cardiac Life Support (ACLS) provider, expires 5/2019
PROFESSIONAL ORGANIZATIONS
--American Academy of Neurology March 2014-Present
--American Association of Nurse Practitioners-2012-Present
PUBLICATIONS
1. Aranca TV, Jones TM, Shaw JD, Staffetti JS, Ashizawa T, Kuo SH, Fogel BL, Wilmot GR, Perlman SL, Onyike CU, Ying SH, Zesiewicz TA. Emerging therapies in Friedreich's ataxia. Neurodegener Dis Manag. 2016;6(1):49-65.
2. Jones TM, Shaw JD, Sullivan K, Zesiewicz TA. Treatment of cerebellar ataxia. Neurodegener Dis Manag. 2014 Oct;4(5):379-392.
PRESENTATIONS
1. Longitudinal Study of Balance Dysfunction in Friedreich’s Ataxia Using the Biodex Balance System SD. Theresa Zesiewicz, MD, FAAN, Clifton Gooch, MD, FAAN, Jeannie Stephenson, PhD, Jennifer Farmer, MS, CGC, Yangxin Huang, PhD, Jason Salemi, PhD, MPH, Israt Jahan, MD, Kelly Sullivan, PhD, Seok Hun Kim, PT, PhD. 2015 International Ataxia Conference Abstract number 102. March 25-28, 2015, Windsor, England.
2. Treatment of Spinocerebellar Ataxia with Intravenous Immune Globulin (IVIG). Theresa A. Zesiewicz, MD, FAAN, Tuan Vu, MD, Kelly L. Sullivan PhD, Clifton Gooch, MD, FAAN, Israt Jahan, MD, MS, Christopher Ward, BS and Seok Kim, PhD. The 66th American Academy of Neurology Annual Meeting-- Abstract number P6.052. April 26-May 3, 2014, Philadelphia, PA.
RESEARCH:
Sub-investigator of multiple research projects as follows:
Active
Source: Cavion, Inc.
Title of Project: “A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of CX-
8998 for Essential Tremor”
Dates of Project: 2017 – present
Active
Source: Sage Therapeutics
Title of Project: “A Phase 2A, Double-blind, Placebo-controlled, Randomized Withdrawal Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of SAGE-217 in the Treatment of Subjects with Essential Tremor (ET)”
Dates of Project: 2017 – present
Active
Source: Takeda
Title of Project: “A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adult Subjects With Friedreich Ataxia.”
Dates of Project: 2017 – present
Active
Source: AbbVie
Title of Project: “M15-563: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP).”
Dates of Project: 2017 – present
Active
Source: Bristol-Myers Squibb Research and Development
Title of Project: “A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Intravenously Administered BMS-986168 in Participants with Progressive Supranuclear Palsy”
Dates of Project: 2017 – present
Active
Source: AbbVie
Title of Project: “M15-562: A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear Palsy.”
Dates of Project: 2016 – present
Active
Principal Investigator: Theresa Zesiewicz
Source: Pfizer
Title of Project: “A 15-Week, Phase 2, Double Blind, Randomized, Placebo-controlled, Flexible Dose Study to Investigate the Efficacy, Safety and Tolerability of PF-06649751 in Subjects with Early Stage Parkinson’s Disease.”
Dates of Project: 2016 – 2017
Active
Principal Investigator: Theresa Zesiewicz
Source: Bristol-Myers Squibb Research and Development
Title of Project: “CN002004: A Multicenter, Open-Label, Long-Term Treatment Study of Intravenously Administered BMS-986168 in Patients with Progressive Supranuclear Palsy Who Participated in Study CN002003”
Dates of Project: 2016 – present
Active
Source: Biohaven Pharmaceutical Holding Company, Ltd.
Title of Project: “A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of BHV-4157 in Adult Subjects with Spinocerebellar Ataxia”
Dates of Project: 2016 – present
Active
Source: Retrotope, Inc.
Title of Project: “Pilot Study of a 3D Motion Device - Feasibility Assessment in Patients with Parkinson’s Disease, Alzheimer’s Disease and Friedreich’s Ataxia (RTMOTION-001)”
Dates of Project: 2015 – present
Active
Source: Reata Pharmaceuticals
Title of Project: “A Phase 2 study of the safety, efficacy, and pharmacodynamics of RTA 408 in the treatment of Friedreich’s ataxia.”
Dates of Project: 2015 – present
Active
Source: Adamas Pharmaceuticals, Inc.
Title of Project: “Open-label safety study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa-Induced Dyskinesia.”
Dates of Project: 2015 – present
Active
Source: Friedreich’s Ataxia Research Alliance; Edison Pharmaceuticals
Title of Project: “Longitudinal Gait and Balance Measurement”
Dates of Project: 2015 – present
Active
Source: Baxter Bioscience (Investigator Initiated Trial)
Title of Project: “An open-label trial of Intravenous Immune Globulin (IVIG) in Treating Spinocerebellar Ataxias”
Dates of Project: 2014 – present
Active
Source: Friedreich’s Ataxia Research Alliance
Title of Project: “Clinical Outcome Measures in Friedreich’s Ataxia”
Dates of Project: 2010 - present
Aims: The primary objective of this study is to find out ways to follow progression of Friedreich’s Ataxia (FRDA) and be able to measure clinical and biochemical changes over a short period of time.
Active
Source: Sagene Pharmaceuticals (Investigator Initiated Trial)
Title of Project: “An open-label trial of oral Selegiline 5 or 10 mg and Tadalafil 2.5mg co-administration to male patients with Parkinson’s Disease and moderate erectile dysfunction”
Dates of Project: 2014 - present
Active
Source: Friedreich’s Ataxia Research Alliance
Title of Project: “An open-label study of the effects of Acetyl-L-Carnitine on cardiovascular outcomes in Friedreich’s Ataxia”
Dates of Project: 2013 - present
Completed
Source: Bristol-Myers Squibb Research and Development
Title of Project: “CN002003: A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intravenously Administered BMS-986168 in Patients with Progressive Supranuclear Palsy.”
Dates of Project: 2015 – 2017
Completed
Source: Friedreich’s Ataxia Research Alliance; Edison Pharmaceuticals
Title of Project: “A Phase 2A Clinical Trial of EPI-743 in Patients with Parkinson’s Disease”
Dates of Project: 2011 – 2016
Aims: To evaluate the effects of EPI-743 in patients with Parkinson’s disease on visual function as assessed by electroretinogram and color vision.
Completed
Source: Friedreich’s Ataxia Research Alliance; Edison Pharmaceuticals
Title of Project: “A Phase 2A Clinical Trial of EPI-743 (Vincerinone) on Visual Function in Friedreich’s Ataxia Patients with Point Mutations”
Dates of Project: 2011 – 2016
Completed
Source: Adamas Pharmaceuticals, Inc.
Title of Project: “ADS-5102 (Amantadine HCl) Extended Release Efficacy and Safety Study in Parkinson’s Disease Patients with Levodopa-Induced Dyskinesia.”
Dates of Project: 2015 – 2016
Completed
Source: USF Department of Neurology (Investigator Initiated)
Title of Project: “Blinded, Randomized Study of Gabapentin and Gabapentin Enacarbil in Patients with Restless Legs Syndrome”
Dates of Project: 2012 – 2016
Completed
Source: Retrotope, Inc.
Title of Project: “A Randomized, Double-Blind, Controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of RT001 in Patients with Friedreich’s Ataxia”
Dates of Project: 2015 – 2016
Completed
Source: Osmotica Pharmaceutical
Title of Project: “A Multicenter, Randomized, Placebo-controlled, Double-blind, 16 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias”
Dates of Project: 2014 – 2016
Completed
Source: Osmotica Pharmaceutical
Title of Project: “A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson’s Disease Subjects with Levodopa-Induced Dyskinesias”
Dates of Project: 2014 – 2016
Completed
Principal Investigator: Theresa Zesiewicz
Source: Synchroneuron, Inc.
Title of Project: “A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Behavior of Orally Administered
Contact this candidate